Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 4, 2012, Pages 379-384

  Zhou, Bo Ting ^a   Zhou, Qiu Hong ^a   Yin, Ji Ye ^a   Li, Guo Liang ^a   Xu, Xiao Jing ^a   Qu, Jian ^a   Liu, Ding ^b   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Carbamazepine; Epilepsy; Genetic polymorphism; Retention rate; SCN1A

Indexed keywords

CARBAMAZEPINE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM CHANNEL NAV1.1; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CHINESE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RETENTION; FEMALE; FOCAL EPILEPSY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEW ONSET FOCAL SEIZURE; POPULATION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; CHILD; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; POLYMORPHISM, GENETIC; SEIZURES; YOUNG ADULT;

EID: 84858953319     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05680.x     Document Type: Article

References (37)

1. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet 2006; 367: 1087-100.
2. Wang WZ, Wu JZ, Wang DS et al. The prevalence and treatment gap in epilepsy in China: An ILAE/IBE/WHO study. Neurology 2003; 60: 1544-5.
3. Fong GC, Kwan P, Hui AC, Lui CH, Fong JK, Wong V. An epidemiological study of epilepsy in Hong Kong SAR, China. Seizure 2008; 17: 457-64.
4. Stewart I. Environmental risk factors for temporal lobe epilepsy: Is prenatal exposure to the marine algal neurotoxin domoic acid a potentially preventable cause? Med. Hypotheses 2010; 74: 466-81.
5. Soundararajan CC, Adhin A, Tripathi M, Prasad HK, Jain S, Vivekanandhan S. Association of CYP2D6 100 C>T and 2850 C>T polymorphisms with generalized tonic clonic seizures among Indians. J. Neural Transm. 2006; 113: 1873-6.
6. Michelucci R, Mecarelli O, Bovo G et al. A de novo LGI1 mutation causing idiopathic partial epilepsy with telephone-induced seizures. Neurology 2007; 68: 2150-1.
7. Song J, Tanouye M. Role for para sodium channel gene 3′ UTR in the modification of Drosophila seizure susceptibility. Dev. Neurobiol. 2007; 67: 1944-56.
8. Gloria-Bottini F, Lucarelli P, Saccucci P et al. Genetic polymorphism and idiopathic generalized epilepsy. Evidence of interaction between haptoglobin and ACP1 systems. Neuropediatrics 2008; 39: 357-8.
9. Schupf N, Ottman R. Risk of epilepsy in offspring of affected women: Association with maternal spontaneous abortion. Neurology 2001; 57: 1642-9.
10. Yuan Y. Methylmercury: A potential environmental risk factor contributing to epileptogenesis. Neurotoxicology 2012; 33: 119-26.
11. Papaleo F, Silverman JL, Aney J et al. Working memory deficits, increased anxiety-like traits, and seizure susceptibility in BDNF overexpressing mice. Learn. Mem. 2011; 18: 534-44.
12. Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission. Arch. Neurol. 2009; 66: 1233-9.
13. Beydoun A, Sachdeo RC, Kutluay E, McCague K, D'Souza J. Sustained efficacy and long-term safety of oxcarbazepine: One-year open-label extension of a study in refractory partial epilepsy. Epilepsia 2003; 44: 1160-5.
14. Escayg A, MacDonald BT, Meisler MH et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS + 2. Nat. Genet. 2000; 24: 343-5.
15. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br. J. Clin. Pharmacol. 2009; 68: 214-20.
16. Schlachter K, Gruber-Sedlmayr U, Stogmann E et al. A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures. Neurology 2009; 72: 974-8.
17. Escayg A, Heils A, MacDonald BT, Haug K, Sander T, Meisler MH. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus: And prevalence of variants in patients with epilepsy. Am. J. Hum. Genet. 2001; 68: 866-73.
18. Kjeldsen MJ, Kyvik KO, Friis ML, Christensen K. Genetic and environmental factors in febrile seizures: A Danish population-based twin study. Epilepsy Res. 2002; 51: 167-77.
19. Lossin C. A catalog of SCN1A variants. Brain Dev. 2009; 31: 114-30.
20. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol. 2008; 66: 304-7.
21. Cossette P, Loukas A, Lafreniere RG et al. Functional characterization of the D188V mutation in neuronal voltage-gated sodium channel causing generalized epilepsy with febrile seizures plus (GEFS). Epilepsy Res. 2003; 53: 107-17.
22. Lossin C, Rhodes TH, Desai RR et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J. Neurosci. 2003; 23: 11289-95.
23. Spampanato J, Kearney JA, de Haan G et al. A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction. J. Neurosci. 2004; 24: 10022-34.
24. Barela AJ, Waddy SP, Lickfett JG et al. An epilepsy mutation in the sodium channel SCN1A that decreases channel excitability. J. Neurosci. 2006; 26: 2714-23.
25. Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 2005; 102: 5507-12.
26. Thompson CH, Kahlig KM, George AL Jr. SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia 2011; 52: 1000-9.
27. Zimprich F, Stogmann E, Bonelli S et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 2008; 49: 1108-9.
28. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981; 22: 489-501.
29. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30: 389-99.
30. Arif H, Buchsbaum R, Pierro J et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch. Neurol. 2010; 67: 408-15.
31. De La Vega FM, Isaac HI, Scafe CR. A tool for selecting SNPs for association studies based on observed linkage disequilibrium patterns. Pac. Symp. Biocomput. 2006; 487-98.
32. Heinzen EL, Yoon W, Tate SK et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 2007; 80: 876-83.
33. Le Gal F, Salzmann A, Crespel A, Malafosse A. Replication of association between a SCN1A splice variant and febrile seizures. Epilepsia 2011; 52: e135-8.
34. Tate SK, Singh R, Hung CC et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 2006; 16: 721-6.
35. Manna I, Gambardella A, Bianchi A et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 2011; 52: e40-4.
36. Majkowski J, Neto W, Wapenaar R, Van Oene J. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia 2005; 46: 648-53.
37. Mauro AM, Bomprezzi C, Morresi S et al. Prevention of early postoperative seizures in patients with primary brain tumors: Preliminary experience with oxcarbazepine. J. Neurooncol. 2007; 81: 279-85.